SCHEMBL1879658

SCHEMBL1879658

N#Cc1ccc2[nH]c3c(c2c1)CC(NC(=O)OCc1ccccc1)CC3

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
ACHE P22303 2/20 0.47
CTSL P07711 1/20 0.46
CTSB P07858 1/20 0.46
CTSK P43235 1/20 0.46
HTR1A P08908 2/20 0.45
HTR1B P28222 2/20 0.45
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
HTR1E P28566 1/20 0.45
HTR7 P34969 1/20 0.45
OPRM1 P35372 1/20 0.45
TMEM97 Q5BJF2 1/20 0.45
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
HTR1D P28221 1/20 0.43
TSHR P16473 1/20 0.43
TLR4 O00206 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1880036 1.00 CA1 (0.47) CA1CA2ACHECTSLCTSB
SCHEMBL1903537 0.87 ACHE (0.51) CA1CA2ACHEHTR1AHTR1B
SCHEMBL13478797 0.87 CA1 (0.48) CA1CA2ACHECTSLCTSB
SCHEMBL1903534 0.87 ACHE (0.51) CA1CA2ACHEHTR1AHTR1B
SCHEMBL14623662 0.87 CA1 (0.48) CA1CA2ACHECTSLCTSB
SCHEMBL1906344 0.84 CA1 (0.46) CA1CA2ACHEHTR1AHTR1B
SCHEMBL1906343 0.84 CA1 (0.46) CA1CA2ACHEHTR1AHTR1B
SCHEMBL1874943 0.84 HTR1B (0.52) HTR1AHTR1BDRD2DRD4HTR1E
SCHEMBL1874947 0.84 HTR1B (0.52) HTR1AHTR1BDRD2DRD4HTR1E
SCHEMBL1875741 0.83 CA1 (0.45) CA1CA2ACHEHTR1AHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
EP-1902026-B1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) LILLY CO ELI (US) 2010-02-17 EP disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
EP-1902026-A2 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) ELI LILLY AND COMPANY (US) 2008-03-26 EP disclosed
WO-2007002181-A2 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) ELI LILLY AND COMPANY (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS AR, SHBG, CYP17A1 CA1 1734/4885CA2 1465/4885ACHE 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.